Cancer screening

Too many US adults are skipping wellness appointments that can help save their lives

Retrieved on: 
Wednesday, June 28, 2023

COLUMBUS, Ga., June 28, 2023 /PRNewswire/ -- Americans don't seem to be on a path to living healthier, longer lives, according to a study released by Aflac Incorporated, a leading provider of supplemental health insurance in the U.S.1The Wellness Matters survey, conducted among 2,001 employed adults in the U.S., examines attitudes, habits and opinions about health and preventive care.

Key Points: 
  • 51% of respondents who have had cancer said their diagnosis came as a result of a routine checkup or screening.
  • The nationally representative survey finds that many — 1 in 4 — simply skip regular checkups because they are feeling healthy.
  • As a result, 72% have avoided a wellness screening, compared to 46% who do not feel it is a barrier.
  • Most (85%) are more likely to go to a routine checkup appointment if a cash incentive was offered to help with the cost.2

Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort

Retrieved on: 
Monday, September 6, 2021

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
  • The Median Technologies iBiopsy Lung Cancer Development Plan was launched in February 2021 , as part of the Companys strategic positioning in early-stage disease diagnosis.
  • Major international studies have shown that LDCT lung cancer screening can reduce mortality by 44% (NELSON Trial, 2018).
  • The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST) consisting of a total of 15,608 lung nodules.

Volpara Health Receives FDA Clearance for Next-Generation Breast Density Algorithm and Architecture

Retrieved on: 
Thursday, July 29, 2021

SEATTLE, July 29, 2021 /PRNewswire/ --Volpara Health,aglobal health technology software leader providing an integrated breast care platform for the delivery of personalizedbreast care, has received FDA clearance for the latest version of its key science algorithm, Volpara Imaging Software (VIS 3.2).

Key Points: 
  • SEATTLE, July 29, 2021 /PRNewswire/ --Volpara Health,aglobal health technology software leader providing an integrated breast care platform for the delivery of personalizedbreast care, has received FDA clearance for the latest version of its key science algorithm, Volpara Imaging Software (VIS 3.2).
  • VIS 3.2 improves the overall robustness of Volpara's industry-leading breast density assessment algorithm, incorporating learnings from artificial intelligence (AI).
  • Since receiving initial FDA clearance for Volpara Imaging Software in 2010, Volpara has now received four additional clearances for the key science algorithm behind its integrated Volpara Breast Health Platforma product suite designed to enable earlier detection of breast cancers through improved mammography quality and workflow, volumetric assessment of breast density, and personalized breast care.
  • The Volpara Breast Health Platform is supported by numerous patents, trademarks, and regulatory registrations, including FDA clearance and CE marking, and is validated by a volume of peer-reviewed publications unrivaled in the breast health industry.

A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI

Retrieved on: 
Thursday, July 29, 2021

According to the study, AI had 28% sensitivity benefit for radiology residents, helping them properly recommend CT exams for potential lung cancer patients, and 30% specificity benefit for radiologists in lung cancer detection, reducing unnecessary CT exams.

Key Points: 
  • According to the study, AI had 28% sensitivity benefit for radiology residents, helping them properly recommend CT exams for potential lung cancer patients, and 30% specificity benefit for radiologists in lung cancer detection, reducing unnecessary CT exams.
  • The study was conducted by Massachusetts General Hospital (MGH) and Lunit, a leading medical AI company.
  • In this consecutive study, the team focused on whether AI can affect the performance of medical professionals in finding lung cancers.
  • Also, radiologists recommended about 30% lesser proportion of unnecessary chest CT examinations (16.4% vs. 11.7%, p

Genetron Health Partners with Guizhou Province’s Dafang County to Lead Liver Cancer Early Screening Project

Retrieved on: 
Thursday, July 29, 2021

BEIJING, July 29, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will work with Guizhou Provinces Dafang County authorities to lead the Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project.

Key Points: 
  • BEIJING, July 29, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will work with Guizhou Provinces Dafang County authorities to lead the Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project.
  • Genetron Health will work with its partners to carry out early screening, diagnosis, treatment, follow-up screenings, and patient management for high risk liver cancer groups in Guizhous Dafang County.
  • Genetron Health will establish a comprehensive cancer prevention and containment model that prioritizes prevention, and integrates it with long-term screening management, diagnosis, and treatment.
  • In 2019, Chinas National Cancer Center used HCCscreens liver cancer early screening liquid biopsy technology in a large-scale prospective cohort study.

AnchorDx's Non-invasive Bladder Cancer Early Detection Test, UriFind, Earns "Breakthrough Device Designation" from FDA

Retrieved on: 
Wednesday, July 21, 2021

This is the first BTD granted to liquid biopsy test for bladder cancer detection in China.

Key Points: 
  • This is the first BTD granted to liquid biopsy test for bladder cancer detection in China.
  • Compared with the traditional gold standard cystoscopy for bladder cancer detection, UriFind is non-invasive, painless and easy to operate allowing for the accurate detection of bladder cancer by simply collecting random urine, providing the Test and conducting methylation detection of exfoliated cell DNA in urine.
  • The Test demonstrates increased advantages in the detection of early, micro, residual and recurrent bladder cancer, and provides a sound basis for the clinical diagnosis of bladder cancer.
  • Founded in 2015, AnchorDx is a world-leading developer of cancer screening and early detection solutions based on methylation technology.

Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic

Retrieved on: 
Tuesday, July 20, 2021

Fight Colorectal Cancer (Fight CRC), the nation's leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will be recognizing clinical researchers and advocates who have demonstrated exceptional leadership during the pandemic in getting people back to routine colorectal cancer screening.

Key Points: 
  • Fight Colorectal Cancer (Fight CRC), the nation's leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will be recognizing clinical researchers and advocates who have demonstrated exceptional leadership during the pandemic in getting people back to routine colorectal cancer screening.
  • The COVID-19 pandemic forced colorectal cancer screening to a standstill in some communities.
  • Fight CRC and Guardant Health have been focused on our shared goal of getting people back to routine cancer screening after the pandemic.
  • To learn more about CRC screening and the importance of raising awareness of colorectal cancer screening, visit FightCRC.org .

AdventHealth Ocala Using Innovative Technology for Lung Cancer Diagnosis

Retrieved on: 
Thursday, July 15, 2021

OCALA, Fla., July 15, 2021 /PRNewswire-PRWeb/ -- AdventHealth Ocala is the 14th hospital in Florida and the first in Marion County to implement the innovative MONARCH platform to fight lung cancer.

Key Points: 
  • OCALA, Fla., July 15, 2021 /PRNewswire-PRWeb/ -- AdventHealth Ocala is the 14th hospital in Florida and the first in Marion County to implement the innovative MONARCH platform to fight lung cancer.
  • "We are excited to add this option technology to our facility as we continue to build on our Lung Cancer Screening Center of Excellence designation and offer a more hopeful future for our patients with lung cancer," said Dr. Michael Torres, Chief Medical Officer, AdventHealth Ocala.
  • "We are focused on earlier detection and diagnosis of lung cancer to increase the chances of survival in our community," said Dr. Raj G. Karunakara, Medical Director of the Lung Health program at AdventHealth Ocala.
  • AdventHealth Ocala is a designated Screening Center of Excellence for Lung Care by the GO2 Foundation for Lung Cancer.

UK - National Institute for Health and Care Excellence (NICE) Issues MedTech Innovation Briefing on 'Trublood®- Prostate' for Precision Non-invasive Prostate Cancer Diagnosis Described by Experts as a 'Game Changer'

Retrieved on: 
Tuesday, July 13, 2021

Trublood-Prostate has the potential to become an innovative, minimally invasive diagnostic test for detecting prostate cancer.

Key Points: 
  • Trublood-Prostate has the potential to become an innovative, minimally invasive diagnostic test for detecting prostate cancer.
  • All experts agreed that the Trublood-Prostate has the potential to be used in addition to standard of care procedures.
  • One expert added that in the future the diagnostic test could be used together with PSA as a precision screening tool for prostate cancer.
  • Datar Cancer Genetics is a leading cancer research company specializing in non-invasive techniques for better diagnosis, treatment decisions, and management of cancer.

Provation and the Australian Commission on Safety and Quality in Health Care strive to improve colonoscopy documentation with new requirements and technology

Retrieved on: 
Tuesday, July 13, 2021

In January 2019, funded by the Australian Government Department of Health, the Commission developed the Colonoscopy Clinical Care Standard.

Key Points: 
  • In January 2019, funded by the Australian Government Department of Health, the Commission developed the Colonoscopy Clinical Care Standard.
  • The Standard includes nine quality statements and a set of four clinical indicators for proper colonoscopy procedure care.
  • By reporting on the Commissions indicators, Australian facilities can increase documentation standardisation for colonoscopies and improve quality patient care.
  • The Australian Commission on Safety and Quality in Health Care is an Australian Government agency that leads and coordinates national improvements in the safety and quality of health care based on the best available evidence.